The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.15910 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Aditya K Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: 5-alpha Reductase Inhibitors, Minoxidil. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Minoxidil and the 5‐alpha reductase inhibitors (5‐ARIs), specifically, dutasteride and finasteride, are usually used to treat pattern hair loss (PHL), but evidence on the relative effectiveness of these drugs is far less for women than men.
Aims
We performed an age‐adjusted network meta‐analysis (NMA) to determine the comparative efficacy of monotherapy with the three agents—in any dosage and administrative route—on PHL in adult women.
Methods
The peer‐reviewed literature was systematically reviewed to obtain data for our NMA. The outcome measure for our NMA was “change in total hair density.” We referred to “regimen” as an “agent and its dosage;” our Bayesian NMA estimated regimens' surface under the cumulative ranking curve (SUCRA) values and pairwise relative effects.
Results
Our NMA used data from 13 trials—across which the following 10 regimens were identified (in decreasing order of SUCRA): 5 mg/day finasteride for 24 weeks (SUCRA = 95.7%), 5% topical minoxidil solution twice daily for 24 weeks (SUCRA = 89.5%), 1 mg/day minoxidil for 24 weeks (SUCRA = 78.1%), 5% topical minoxidil foam 1 half capful/day for 24 weeks (SUCRA = 66.5%), 3% topical minoxidil solution 1 mL twice daily for 24 weeks (SUCRA = 45.1%), 2% topical minoxidil solution 1 mL twice daily for 24 weeks (SUCRA = 44.6%), 5% topical minoxidil solution 1 mL/day for 24 weeks (SUCRA = 41.7%), 0.25 mg/day minoxidil for 24 weeks (SUCRA = 35.5%), 1.25 mg/day finasteride for 24 weeks (SUCRA = 24.8%) and 1 mg/day finasteride for 24 weeks (SUCRA = 4.3%).
Conclusion
Our findings can improve clinical guidelines and help dermatologists manage female PHL more optimally with the available options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- School of Pharmacy, BRAC University, Dhaka, Bangladesh.
ORCID-Profile: Aditya K Gupta, Mesbah Talukder
Zitieren
APA
Gupta, A. K., Wang, T., Bamimore, M. A., & Talukder, M. (2024). The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15910
Vancouver
Gupta AK, Wang T, Bamimore MA, Talukder M. The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.15910
BibTeX
@article{Gupta2024,
author = {Gupta, Aditya K and Wang, Tong and Bamimore, Mary A and Talukder, Mesbah},
title = {The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.15910}
}
EUVIMED